GDC-9545

giredestrant · Genentech, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GDC-9545, covering 2021-04-28 to 2026-02-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer [Phase 1]

See pricing